FDMT
4D Molecular Therapeutics, Inc.11.52
+0.57+5.21%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
658.20MP/E (TTM)
-Basic EPS (TTM)
-3.75Dividend Yield
0%Recent Filings
8-K
4DMT 2025 results, cash to 2028
4D Molecular Therapeutics reported full year 2025 financials on March 18, 2026, posting $85M collaboration revenue from Otsuka deal and $514M cash runway into H2 2028. R&D expenses climbed to $196M on 4D-150 Phase 3 wet AMD trials, with enrollment completed ahead of schedule; topline data due H1 2027. Net loss narrowed to $140M. Leadership expanded for late-stage push.
10-K
FY2025 results
4D Molecular Therapeutics posted FY2025 net loss of $140.1M, improved from $160.9M in FY2024, with R&D expenses up 38% to $195.7M driven by Phase 3 trials for lead candidate 4D-150 in wet AMD and DME. Q4 revenue hit $85.2M from Otsuka APAC licensing deal, offsetting ongoing cash burn. Cash reserves stood at $514M end-2025, funding operations into late 2026 amid accelerated 4FRONT-1 enrollment completion. No quarterly breakdowns disclosed. Debt-free liquidity supports pipeline. Clinical trial failures could derail momentum.
8-K
Exchanges shares for pre-funded warrants
4D Molecular Therapeutics swapped 6.6 million common shares held by RA Capital and BVF for equivalent pre-funded warrants on January 22, 2026, exercisable at $0.0001 per share with 4.99%/9.99% ownership caps. Shares outstanding fell to 51 million as of January 23. Warrants stay alive until fully exercised. This unregistered exchange sidesteps dilution while locking in big holders.
8-K
Cash $514M; exec shifts
4D Molecular Therapeutics reported $514M in preliminary cash and equivalents as of December 31, 2025. Dr. Fariborz Kamal resigned as President and COO that day, shifting to part-time Chief Technical Advisor; CEO David Kirn added President duties effective January 1, 2026. Board named biopharma veteran Glenn Sblendorio director January 5. Leadership evolves smoothly.
8-K
Expands Phase 3 enrollment to 480
4D Molecular Therapeutics announced protocol amendments to its 4FRONT-1 and 4FRONT-2 Phase 3 trials for 4D-150 in wet AMD, boosting target enrollment from 400 to 480 patients per trial on December 10, 2025. Amendments sharpen noninferiority power to ~4 letters for global regulators like Japan PMDA and EMA, backing Otsuka's Asia-Pacific push amid bigger commercial vistas. Enrollment stays on track. No financial hit.
IPO
Employees
Sector
Industry
ADVM
Adverum Biotechnologies, Inc.
4.36+0.00
CCCC
C4 Therapeutics, Inc.
2.26-0.17
DSGN
Design Therapeutics, Inc.
9.62+0.50
IRD
Opus Genetics, Inc.
2.14+0.01
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
NGNE
Neurogene Inc.
19.53-0.73
QURE
uniQure N.V.
21.89+1.46
RGNX
REGENXBIO Inc.
14.11+0.28
TRDA
Entrada Therapeutics, Inc.
11.37+0.34